| h-97aa8486 | Stress Granule Phase Separation Modulators | 0.72 | 0.80 | G3BP1 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-68d9c9c1 |
| h-aa2d317c | Magnetosonic-Triggered Transferrin Receptor Clustering | 0.72 | 0.65 | TFR1 | debated | 2026-04-02 | sda-2026-04-01-gap-008 |
| h-35f04e1b | Retinal Vascular Microcirculation Rescue | 0.72 | 0.40 | PDGFRB/ANGPT1 | debated | 2026-04-02 | sda-2026-04-01-gap-012 |
| h-3a990993 | Compromised Lysosomal Acidification and Trafficking Due to Neuronal V-ATPase Sub | 0.72 | 0.75 | ATP6V0/ATP6V1 subunits, ARL8B-SYX17 axis | proposed | 2026-04-26 | SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c |
| h-trem2-f3effd21 | TREM2-DAP12 Signalosome Enhancement — Boosting PI3K-AKT-mTOR Axis for Microglial | 0.72 | 0.62 | TREM2, TYROBP, SYK, PI3K | proposed | 2026-04-05 | SDA-2026-04-02-gap-001 |
| h-15336069 | APOE Isoform Conversion Therapy | 0.72 | 0.45 | APOE | proposed | 2026-04-03 | sda-2026-04-01-gap-auto-fd6b1635d9 |
| h-b948c32c | Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides | 0.72 | 0.30 | APOE, LRP1, LDLR | debated | 2026-04-02 | sda-2026-04-01-gap-008 |
| h-530326b97069 | SASP-Secreted MMP-9 from Senescent Microglia Generates Pathological TDP-43 C-Ter | 0.72 | 0.30 | MMP9 → TARDBP (C-terminal fragments) → cytoplasmic aggregati | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260425215446 |
| h-1111ac0598 | C9orf72 DPRs Impair Autophagy Receptor Docking on Stress Granules | 0.72 | 0.72 | C9orf72, p62/SQSTM1, OPTN | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041423-3a6aa4ab |
| h-var-de1677a080 | TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration | 0.72 | 0.80 | TREM2 | proposed | 2026-04-12 | SDA-2026-04-26-trem2-showcase |
| h-7e0b5ade | Circadian-Synchronized LRP1 Pathway Activation | 0.71 | 0.40 | LRP1, MTNR1A, MTNR1B | debated | 2026-04-02 | sda-2026-04-01-gap-008 |
| h-trem2-fe8c644a | Soluble TREM2 (sTREM2) as Therapeutic Mimic — Decoupling Phagocytosis from Infla | 0.71 | 0.65 | TREM2, ADAM10, ADAM17 | proposed | 2026-04-05 | SDA-2026-04-02-gap-001 |
| h-f373e16bb108 | EZH2-Mediated H3K27me3 Spreading in Senescent ALS Microglia Silences Neuroprotec | 0.71 | 0.28 | EZH2 (PRC2) → H3K27me3 silencing of BDNF, GRN, TREM2, MerTK | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260425215446 |
| h-0758b337 | Purinergic Signaling Polarization Control | 0.71 | 0.70 | P2RY1 and P2RX7 | debated | 2026-04-02 | sda-2026-04-01-gap-007 |
| h-var-18aae53fe9 | TREM2-ASM Crosstalk in Microglial Lysosomal Senescence | 0.71 | 0.78 | SMPD1 | promoted | 2026-04-12 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-1f9e65f394 | Liquid-to-Solid Transition Pathology Reveals Granule Weak Points | 0.71 | 0.82 | TDP-43, FUS, TIA1, G3BP1 | debated | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041428-53b81741 |
| h-583535bb | Gut-BBB Axis: Tributyrin/Butyrate HDAC Inhibition Epigenetically Restores Claudi | 0.71 | 0.74 | CLDN5 | proposed | 2026-04-26 | SDA-2026-04-26-gap-bbb-permeability-biomarker-20260426 |
| hyp_test_656bc496 | Test: TREM2 enhances amyloid clearance | 0.71 | 0.33 | TREM2 | proposed | 2026-04-17 | test-hypothesis-fixtures-v1 |
| h-fcd38787 | TGF-β1–SMAD2/3 Axis as Master Suppressor of Microglial Trained Immunity | 0.71 | 0.78 | TGFBR1/TGFBR2 → SMAD4 → SMAD2/3 | proposed | 2026-04-26 | SDA-2026-04-08-gap-debate-20260406-062033-ad87c3fb |
| h-de579caf | Circadian Glymphatic Rescue Therapy (Melatonin-focused) | 0.71 | 0.55 | MTNR1A | debated | 2026-04-02 | sda-2026-04-01-gap-v2-18cf98ca |
| h-9588dd18 | Early Proteasome Restoration Therapy | 0.71 | 0.75 | PSMC | promoted | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-4113b0e8 | Noradrenergic-Tau Propagation Blockade | 0.71 | 0.45 | ADRA2A | debated | 2026-04-02 | sda-2026-04-01-gap-v2-18cf98ca |
| h-5edc4a7e0558 | Excess orexin-A worsens AD cognition through wake-driven amyloid production | 0.71 | 0.69 | HCRT | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-184240-f72e77ae |
| h-64d92165 | APOE4-Specific Microglial Metabolic Rescue | 0.71 | 0.66 | APOE, ABCA1, LDLR | proposed | 2026-04-04 | SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 |
| h-a9571dbb | HDAC3-Selective Inhibition for Clock Reset | 0.71 | 0.60 | HDAC3 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-bc5f270e |
| h-d2d37a81eeaa | ACSL4 lipid remodeling creates ferroptosis-prone ALS membranes | 0.71 | 0.69 | ACSL4 | proposed | 2026-04-26 | SDA-2026-04-26-gap-ferroptosis-mnd-768eaeba1be3 |
| h-78c49508e9 | NRF2 Activation Provides Neuroprotection Across ALS, AD, and PD | 0.71 | 0.72 | NFE2L2 (NRF2) | proposed | 2026-04-28 | SDA-TEST-PREREG-003 |
| h-b9794c8e29 | Microglial TREM2 Activation Reduces Amyloid-Associated Neurotoxicity | 0.71 | 0.78 | TREM2 | proposed | 2026-04-28 | SDA-TEST-PREREG-003 |
| h-75fd56f128 | RAB29 Is the Critical Molecular Switch That Determines Whether LRRK2 Signal Ampl | 0.71 | 0.70 | RAB29 | proposed | 2026-04-26 | SDA-2026-04-23-gap-debate-20260417-033119-54941818 |
| h-4032affe2f | Microglial Disease-Associated States: TREM2-Independent Pathways Driving Neuroin | 0.71 | 0.68 | APOE | proposed | 2026-04-22 | SDA-2026-04-02-gap-seaad-debate-v4 |
| h-d9793012de | Conformational-Selective Blocking of Tau Uptake Reveals Therapeutic Window in Ne | 0.71 | 0.72 | LRP1, HSPG (SDC3, GPC1), tau conformations | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062052-7bcf4b6c |
| h-82634b359b | H4: Senomorphic Compounds Preserve Astrocyte Function While Reversing Senescence | 0.71 | 0.65 | MTOR; MEGF10; MERTK | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062101-5d7b9dc0 |
| h-3d993b5d | Metabolic Circuit Breaker via Lipid Droplet Modulation | 0.71 | 0.60 | PLIN2 | debated | 2026-04-02 | sda-2026-04-01-gap-009 |
| h-5e68b4ad | Autophagosome Maturation Checkpoint Control | 0.71 | 0.73 | STX17 | debated | 2026-04-02 | sda-2026-04-01-gap-011 |
| h-82922df8 | Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition | 0.71 | 0.65 | LOX/LOXL1-4 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-immunity-c64967ab | TREM2-APOE4 Axis Drives Metabolic Inflexibility in DAM | 0.71 | 0.72 | TREM2, APOE4, LDHA | open | 2026-04-24 | |
| h-var-bed9f3b7ed | TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration | 0.71 | 0.80 | TREM2 | superseded | 2026-04-12 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-9d29bfe5 | Membrane Cholesterol Gradient Modulators | 0.71 | 0.85 | ABCA1/LDLR/SREBF2 | promoted | 2026-04-02 | SDA-2026-04-01-gap-lipid-rafts-2026-04-01 |
| h-8597755b | Orexin-Microglia Modulation Therapy | 0.71 | 0.50 | HCRTR2 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-18cf98ca |
| h-587ea473 | Creatine Kinase System Capacity as Neural Energy Reserve Biomarker | 0.71 | 0.50 | CKB | proposed | 2026-04-17 | SDA-2026-04-04-gap-debate-20260403-222618-c698b06a |
| h-d7121bcc | TET2-Mediated Demethylation Rejuvenation Therapy | 0.71 | 0.68 | TET2 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-bc5f270e |
| h-b3d6ecc2 | Lysosomal Enzyme Trafficking Correction | 0.71 | 0.65 | IGF2R | debated | 2026-04-02 | sda-2026-04-01-gap-011 |
| h-fb56c8a0 | Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation | 0.71 | 0.70 | SDC1 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-SDA-2026-04-26-gap | CSF/Plasma AQP4 Polarization Index as a Novel Biomarker of Astrocyte Glymphatic | 0.71 | 0.50 | AQP4 | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260426-001521 |
| h-SDA-2026-04-26-gap | Plasma Claudin-5 Proteolytic Fragments Distinguish Paracellular BBB Breakdown fr | 0.71 | 0.41 | CLDN5 | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260426-002803 |
| h-SDA-2026-04-26-gap | Soluble PDGFRβ as a Peripheral Indicator of Pericyte-Mediated Blood-Brain Barrie | 0.71 | 0.43 | PDGFRB (Platelet-Derived Growth Factor Receptor Beta) | proposed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260426-011448-7c85f5dc |
| h-5cbf67bf98 | Spatiotemporal coupling between TRPML1-mediated lysosomal calcium release and ca | 0.70 | 0.65 | TRPML1/MCOLN1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062150-387cb0ba |
| hyp_test_0a572efb | Test: TREM2 enhances amyloid clearance | 0.70 | 0.40 | TREM2 | archived | 2026-04-04 | test-hypothesis-fixtures-v1 |
| h-2c776894 | Ferroptosis Inhibition for α-Synuclein Neuroprotection | 0.70 | 0.75 | GPX4 | promoted | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-470ff83e | Microglial Efferocytosis Enhancement via GPR32 Superagonists | 0.70 | 0.50 | CMKLR1 | debated | 2026-04-02 | sda-2026-04-01-gap-014 |